This Week We Have A Paper Due Concerning The Cardiovascular Systemp This week we have a paper due concerning the cardiovascular system. Please use the scenario below to base your paper on. It is not the goal to necessarily change ALL medications, however, that might be the case. In short, I am looking for concrete examples of how you back up your decisions with proper resources and guidelines. Talk to you soon! Patient CB has a history of strokes. The patient has been diagnosed with type 2 diabetes, hypertension, and hyperlipidemia. Drugs currently prescribed include the following: Glipizide 10 mg po daily, HCTZ 25 mg daily, Atenolol 25 mg po daily, Hydralazine 25 mg qid, Simvastatin 80 mg daily, Verapamil 180 mg CD daily.
Paper For Above instruction The intricate interplay of the cardiovascular system and its management becomes critically evident when evaluating a patient like CB, who presents with multiple comorbidities including a history of strokes, type 2 diabetes, hypertension, and hyperlipidemia. Effective management necessitates a comprehensive understanding of pathophysiology, current pharmacotherapy, and adherence to clinical guidelines to optimize outcomes while minimizing adverse effects. The patient's current pharmacological regimen includes Glipizide, HCTZ, Atenolol, Hydralazine, Simvastatin, and Verapamil. Each medication targets different aspects of CB’s health conditions, but their combination requires careful assessment to prevent drug interactions and ensure all therapeutic goals are met. **Management of hypertension and cardiovascular risk** Atenolol, a beta-blocker, is commonly prescribed for hypertension and to reduce cardiovascular risk post-stroke (Wiysonge et al., 2017). However, recent guidelines suggest that in certain hypertensive populations, especially with comorbidities like diabetes, agents such as ACE inhibitors or ARBs might be preferable due to their additional renal protective effects (Whelton et al., 2018). Nonetheless, atenolol remains effective for rate control, especially in patients with concomitant ischemic heart disease. Hydralazine, a direct arterial vasodilator, is often used in resistant hypertension or acute settings but is sometimes associated with adverse effects like headaches and tachycardia. It’s crucial to monitor blood pressure and heart rate closely to prevent hypotension or reflex tachycardia (Joffe et al., 2014).